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Key points
• Cortical glycine receptors (GlyRs) flux chloride based on a local chloride gradient set by chloride
transporters; this gradient changes with age.
• In acute slices from the developing mouse visual cortex, tonic GlyR activity increases
spontaneous excitatory neurotransmitter release in a calcium-dependent manner.
• Glycine transporters, localized mainly to astrocytes, regulate this tonic activity.
• After a critical period of early development, GlyRs are no longer tonically active and become
hyperpolarizing, inhibiting spontaneous neurotransmitter release.
• These results define mechanisms that contribute to baseline neurotransmission during critical
periods of neuronal development, and help identify synaptic functions that could be impacted
by GlyR dysfunction.
Abstract Glycine receptors (GlyRs) are found in most areas of the brain, and their dysfunction
can cause severe neurological disorders. While traditionally thought of as inhibitory receptors,
presynaptic-acting GlyRs (preGlyRs) can also facilitate glutamate release under certain
circumstances, although the underlying molecular mechanisms are unknown. In the current
study, we sought to better understand the role of GlyRs in the facilitation of excitatory neuro-
transmitter release in mouse visual cortex. Using whole-cell recordings, we found that pre-
GlyRs facilitate glutamate release in developing, but not adult, visual cortex. The glycinergic
enhancement of neurotransmitter release in early development depends on the high intracellular
to extracellular Cl− gradient maintained by the Na+–K+–2Cl− cotransporter and requires Ca2+
entry through voltage-gated Ca2+ channels. The glycine transporter 1, localized to glial cells,
regulates extracellular glycine concentration and the activation of these preGlyRs. Our findings
demonstrate a developmentally regulated mechanism for controlling excitatory neurotransmitter
release in the neocortex.
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Introduction
Glycine receptors (GlyRs) are found throughout the CNS.
They are localized to pre- and postsynaptic membranes
(Dahan et al. 2003; Danglot et al. 2004), where they
play a critical role in both inhibitory and excitatory
neurotransmission. GlyR function is controlled by both
subunit composition and local glycine concentrations
(Schmieden et al. 1992; Yoon et al. 1998). The importance
of glycinergic transmission is underscored by findings
that disruptions in glycine homeostasis, such as hyper-
glycinemia, contribute to severe neurological disorders
that manifest during early development (Singer et al. 1989;
Steiner et al. 1996; Hoover-Fong et al. 2004). Despite this
critical role, the developmental mechanisms that regulate
glycinergic functions are poorly understood.
GlyRs primarily flux Cl−; thus, whether these receptors
are depolarizing or hyperpolarizing depends on the local
Cl− gradient (Wang & Xu, 2006). Two major Cl− trans-
porters help to establish this gradient; the Na+–K+–Cl−
cotransporter 1 (NKCC1) transports Cl− into the cell,
whereas the K+–Cl− cotransporter 2 (KCC2) pumps
Cl− out of the cell (Payne et al. 2003). During early
development, NKCC1 expression is high and KCC2
expression is low, creating a high intracellular ([Cl−]i)
to extracellular ([Cl−]o) Cl− concentration gradient. A
developmental increase in the ratio of KCC2 to NKCC1
causes an increase in the relative [Cl−]o (Payne et al. 2003).
Consequently, GlyRs are generally depolarizing during
early development and become progressively more hyper-
polarizing with maturation, as dictated by the Cl− gradient
(Turecek & Trussell, 2001; Ye et al. 2004; Song et al. 2006;
Lee et al. 2009).
GlyRs can act presynaptically to modulate release of
neurotransmitters in several systems (Turecek & Trussell,
2001; Jeong et al. 2003; Kawa, 2003; Kubota et al.
2010; Waseem & Fedorovich, 2010). The developmental
regulation of these presynaptic-acting GlyRs (preGlyRs)
suggests that by modulating neurotransmitter release
they might play an important role in establishing
synaptic function during formative periods of cortical
development. The primary visual cortex provides an
attractive model to study postnatal development, but
the contribution of preGlyRs to the maintenance
of basal neurotransmitter release has not been
addressed.
In the present study we took advantage of the
ability of GlyRs to regulate spontaneous, action
potential-independent neurotransmitter release (Turecek
& Trussell, 2001; Jeong et al. 2003; Kawa, 2003; Lee et al.
2009; Kubota et al. 2010; Waseem & Fedorovich, 2010)
to investigate mechanisms underlying preGlyR function.
Our data indicate that preGlyRs are tonically activated by
glycine, most likely from astrocytes, and that these pre-
GlyRs activate voltage-gated calcium channels (VGCCs)




All animal experiments were approved by the Institutional
Animal Care and Use Committee of the University of
North Carolina at Chapel Hill.
Subjects
C57BLJ/6 mice were purchased from Charles River
Laboratories (Wilmington, MA, USA) and bred in-house.
Mice (n = 163) were examined between postnatal day
(P)13 and P40. Mice were maintained on a 12:12 h
light:dark cycle and fed ad libitum.
Brain slice preparation
Slices of visual cortex were prepared from mice using
standard methods (Corlew et al. 2007; Yashiro et al.
2009). Briefly, mice were anaesthetized with pento-
barbital sodium (40 mg kg−1, I.P.) and decapitated upon
disappearance of the corneal reflex. Brains were rapidly
removed and immersed in oxygenated ice-cold dissection
buffer (in mM: NaCl, 87; KCl, 2.5; NaH2PO4, 1.25;
NaHCO3, 25; sucrose, 75; dextrose, 10; ascorbic acid,
1.3; MgCl2, 7; CaCl2, 0.5). The visual cortex was cut in
300 μm coronal slices using a vibrating microtome (Leica
VT1200S, Buffalo Grove, IL, USA). Slices were allowed to
recover for 30 min in a submersion chamber at 35◦C filled
with standard artificial cerebrospinal fluid (ACSF; in mM:
NaCl, 124; KCl, 3; Na2PO4, 1.25; NaHCO3, 26; MgCl2, 1;
CaCl2, 2; dextrose, 20; saturated with 95% O2, 5% CO2;
∼315 mosmol l−1 and pH ∼7.25), and were then kept
at room temperature for a minimum of 30 min. Visual
cortex slices were transferred to a submersion-recording
chamber and continuously perfused at 2 ml min−1 with
standard ACSF warmed to 30◦C.
Voltage-clamp recordings
Patch pipettes (3–5 M tip resistance) were filled
with an internal solution containing (in mM): KCl,
20; potassium gluconate, 100; Hepes, 10; Mg-ATP,
4; Na-GTP, 0.3; sodium phosphocreatine, 10; 0.01%
Alexa 488 (wt/vol), with the pH adjusted to
7.25 and osmolarity adjusted to ∼295 mosmol l−1.
4,4′-Diisothiocyanatostilbene-2,2′-disulfonic acid (DIDS;
1 mM) was included in the internal solution, to block post-
synaptic Cl− channels (Albertson et al. 1996; Hollrigel et al.
1998; Leewanich et al. 1998). Cells were voltage-clamped
C© 2012 The Authors. The Journal of Physiology C© 2012 The Physiological Society
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in the whole-cell configuration using a Multiclamp 700B
amplifier. Data were digitized using a Digidata 1440A
(Molecular Devices, Sunnyvale, CA, USA), and acquired
and analysed using pCLAMP 10.2 software (Molecular
Devices). Only cells that had confirmed pyramidal
morphology with Rseries < 30 M and exhibiting <20%
change in Rinput, Rseries and Iholding for the duration of the
experiment were included in the analysis.
AMPA receptor-mediated miniature excitatory post-
synaptic currents (mEPSCs) were recorded at −70 mV
in the presence of tetrodotoxin (TTX; 200 nM)
and bicuculline methiodide (BMI; 30 μM) to block
voltage-gated sodium channels and GABAA receptors,
respectively. mEPSC amplitude and frequency were
measured before, during and after drug bath application.
Events were identified and detected by their rapid rise
time (<3 ms) and characteristic shape using an auto-
matic template detection program (pCLAMP; Molecular
Devices; Clements & Bekkers, 1997). All events were
manually verified; only events with a monotonic rise
time and exponential decay were included in the analysis.
Normalized values for frequency and amplitudes were
used for mEPSC data analysis. An average of ∼1300 events
was analysed for each neuron.
Data collection and statistics
Experiments were conducted in a manner that roughly
interleaved experimental and control conditions, and were
analysed blinded to experimental condition. Two-tailed
paired or unpaired Student’s t tests were employed where
appropriate; for comparison of multiple groups, we used
a one-way ANOVA. For all tests, the level of significance
was P < 0.05.
Electron microscopy
Material was from three P17 mice, perfusion-fixed
with 4% depolymerized paraformaldehyde; in one
mouse 0.1% glutaraldehyde was added to the fixative.
Following perfusion, brains were removed and stored
in phosphate-buffered saline (pH 7.4); in two mice,
the brain was first postfixed in 4% depolymerized
paraformaldehyde overnight. Fifty micrometer coronal
sections through the visual cortex were cut with a
Vibratome and stored in phosphate buffer at 4◦C. After
pretreatment for 10 min in 3% hydrogen peroxide (to
inactivate endogenous peroxidase activity) and then 10%
normal donkey serum (to block non-specific binding),
sections were incubated on a shaker overnight in primary
polyclonal anti-glycine transporter 1 (GlyT1) antiserum,
raised in goat (1:2000; Millipore, AB1770; Billerica,
MA, USA). After rinsing and additional blocking with
2% normal donkey serum, sections were incubated for
1 h in biotinylated anti-goat IgG secondary antibody
(Jackson ImmunoResearch, West Grove, PA, USA), then
for 1 h in ExtraAvidin (Sigma, St Louis, MO, USA),
1:5000 dilution. After visualization of antibody binding
sites with a nickel-enhanced diaminobenzidine (DAB)
reaction, sections in phosphate buffer were treated for
40 min in 0.5% OsO4, rinsed in 0.1 M maleate buffer,
pH 6.0, stained en bloc with 1% uranyl acetate for 45 min,
then dehydrated in graded ethanols and infiltrated in
plastic (Spurr epoxy resin, Electron Microscopy Sciences,
Hatfield, PA, USA). Sections were flat-embedded between
two sheets of ACLAR plastic sandwiched by glass slides and
heat-polymerized for 48 h at 60◦C. Chips of embedded
tissue were cut out from the cured wafer and glued
to epoxy blanks. Thin sections (∼60 nm) were cut on
an ultramicrotome, collected on copper mesh grids,
post-stained with uranyl acetate and Sato’s lead, and
examined on a Tecnai 12 transmission electron micro-
scope. Images were collected with a 12 bit Gatan
1024 × 1024 cooled CCD camera. Brightness and contrast
of final images were adjusted using Adobe Photoshop.
Chemicals
Drugs were made as 100×–1000× stock solutions in
water or DMSO, and diluted immediately before use
in ACSF. All drugs were obtained from Sigma, except:
TTX, BMI and D,L-2-amino-5-phosphonopentanoic
acid (D,L-APV) were obtained from Ascent Scientific
(Princeton, NJ, USA); N-[3-(4′-fluorophenyl)-3-(4′-
phenylphenoxy)propyl] sarcosine (NFPS) and sarcosine
were obtained from Tocris (Ellisville, MO, USA); and
cyclopiazonic acid (CPA) was obtained from Calbiochem
(La Jolla, CA, USA).
Results
GlyR activity enhances excitatory neurotransmitter
release in developing visual cortex
Changes in mEPSC frequency, but not amplitude, by GlyR
agonists and antagonists have been used as a readout
of preGlyR function (Jeong et al. 2003; Kawa, 2003;
Lee et al. 2009). We therefore prepared visual cortex
slices from P13–18 mice, and examined the effects of
GlyR agonists and antagonists on mEPSC frequency and
amplitude in layer (L)2/3 pyramidal neurons. We included
1 mM DIDS in the internal recording solution to block
postsynaptic GlyR function (30 ± 8% of baseline-evoked
glycine current, n = 13, P < 0.001; paired Student’s t test;
Inoue, 1985; Parker et al. 1988; Song et al. 2006).
Glycine transiently increased the frequency of mEPSCs
in neurons in a dose-dependent manner (Fig. 1A and B;
100 nM: 98 ± 6% of baseline, P > 0.05; 1 μM: 121 ± 5% of
baseline, P < 0.05; 1 mM: 142 ± 7% of baseline, P < 0.001;
C© 2012 The Authors. The Journal of Physiology C© 2012 The Physiological Society
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Figure 1. Glycine promotes neurotransmitter release in
developing V1
Aa, schematic of recording and experimental design. Glycine was
acutely applied after a 10 min baseline period and then washed out
after an additional 10 min. Ab, example whole-cell recording from a
L2/3 pyramidal cell depicting miniature excitatory postsynaptic
currents (mEPSCs) recorded at baseline, during bath application of
1 μM glycine, and after washout of glycine in a visual cortex slice
from a P15 mouse. Ac, group data show the time course over which
ANOVA). We wanted to use the lowest concentration that
reliably gave us an increase in mEPSC frequency; therefore,
we used 1 μM glycine for further experiments. mEPSC
amplitude was unchanged with glycine application (Fig.
1C), further supporting that these effects are not post-
synaptic in origin. These data demonstrate that glycine can
promote action potential-independent neurotransmitter
release. We next wanted to determine if glycine could
enhance action potential-driven neurotransmitter release.
We thus tested the effect of glycine (1 μM) on synaptic
responses recorded in L2/3 and evoked by L4 stimulation.
Under these conditions, we failed to see an effect of glycine
on evoked EPSC amplitudes (Fig. 2A and B). We also
found that glycine failed to alter the paired-pulse ratio
(PPR), a gauge of neurotransmitter release (Dobrunz
& Stevens, 1997), at any stimulus interval tested (Fig.
2C). Together, these findings indicate that glycine is
depolarizing at P13–18 and can cause a large increase
in spontaneous, action potential-independent transmitter
release, but under our recording conditions we were not
able to detect a role for GlyRs in action potential-driven
neurotransmitter release.
To test if GlyRs tonically regulate spontaneous, action
potential-independent neurotransmitter release onto L2/3
pyramidal neurons, we recorded the effects of bath
application of the GlyR antagonist strychnine on mEPSC
frequency and amplitude. Strychnine (3 μM) significantly
reduced mEPSC frequency (Fig. 3B; 81 ± 4% of base-
line, P < 0.01; t test) without changing mEPSC amplitude
(Fig. 3C; 99 ± 3% of baseline, P > 0.6). This suggests
that glycine at ambient levels promotes GlyR-mediated
spontaneous neurotransmitter release.
At the concentration used here, strychnine has a
high specificity for blocking GlyRs (Okabe et al. 2004).
However, glycine can also influence neurotransmitter
release indirectly, by binding to presynaptic NMDA
receptors (NMDARs; Johnson & Ascher, 1987), which
can promote neurotransmitter release at these young
ages (Woodhall et al. 2001; Corlew et al. 2007; Brasier
& Feldman, 2008). We therefore tested the effects of
glycine reversibly enhanced mEPSC frequency. A4, scatterplot
demonstrating that glycine reversibly enhances mEPSC frequency in
7 individual L2/3 pyramidal neurons (boxes). Red lines represent
averages. B, cumulative probability distributions of mEPSC frequency
(Ba) and amplitude (Bb) following glycine application (1 μM). Glycine
shortened inter-event interval, with no obvious effects on amplitude.
C, averaged normalized mEPSC frequency to illustrate acute effects
of various glycine concentrations (100 nM–1 mM), expressed as a
percentage of baseline. Asterisks denote bars significantly different
from control (P < 0.05). D, averaged normalized data illustrate that
glycine did not significantly alter mEPSC amplitude. Sample sizes in C
and D are given within the bars. The mEPSC frequencies and
amplitudes were normalized to the averaged baseline levels before
acute drug application. ACSF, artificial cerebrospinal fluid.
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100 μM taurine, which has been reported to exhibit high
specificity for GlyRs when used at this concentration
(Yu et al. 2008). Taurine significantly increased mEPSC
frequency (Fig. 3B; 115 ± 3% of baseline, P < 0.01; t test)
with only modest and non-significant effects on amplitude
(Fig. 3C; 107 ± 5% of baseline, P > 0.1). In a sub-
set of experiments, we included D,L-APV (100 μM), an
NMDAR-selective antagonist, in the extracellular solution
to prevent any possible taurine activation of NMDARs,
and saw similar results (frequency: 114 ± 2% of baseline;
amplitude: 109 ± 6% of baseline).
Strychnine, but not D,L-APV, pre-incubation occluded
the glycine-mediated increase in mEPSC frequency (Fig.
3B; strychnine; 98 ± 3% of baseline vs. control 124 ± 3%
of baseline, P < 0.02: D,L-APV; 125 ± 6% of baseline
vs. control 120 ± 5% of baseline, P > 0.05; unpaired
t tests), further supporting that strychnine-sensitive
GlyR activation, not NMDAR activation, underlies
glycine-induced increases in neurotransmitter release. As
additional evidence, we bath-applied the agonist D-serine
(50 μM), which binds with high affinity to glycine sites
on NMDARs, but not GlyRs. D-Serine had no effect
on mEPSC frequency (Fig. 3B; 99 ± 4% of baseline,
P > 0.5). Thus, multiple pharmacological manipulations
indicated that glycine promotes spontaneous neuro-
transmitter release in developing visual cortex via GlyRs,
and not via NMDARs.
It remains possible that the glycine-mediated effects
on neurotransmitter release occur through a novel class
of excitatory GlyRs composed of the NMDAR subunits
NR1 and NR3A, as these diheteromers act as GlyRs and
show little block by classic NMDAR antagonists, including
D,L-APV (Das et al. 1998; Chatterton et al. 2002). To
test whether NR1/NR3A diheteromers might underlie
the glycine-mediated effects on neurotransmitter release,
we applied glycine to visual cortical slices from NR3A
knock-out mice (Das et al. 1998) bathed in D,L-APV.
Similar to recordings in wild-type mice, L2/3 neurons
in NR3A knock-out mice exhibited a glycine-induced
enhancement of mEPSC frequency (Fig. 3B; 120 ± 13%
of baseline, compared with 124 ± 9% of baseline in
wild-type mice, P > 0.9), without affecting mEPSC
amplitude (Fig. 3C; 104 ± 6% of baseline, compared with
102 ± 2% of baseline in wild-type mice, P > 0.2). We
conclude that glycine promotes neurotransmitter release
in the developing cortex by activating strychnine-sensitive
GlyRs, rather than NMDARs or NR1/NR3A-containing
excitatory GlyRs.
These experiments, which show that multiple glycine
agonists/antagonists alter mEPSC frequency in the pre-
sence of postsynaptic GlyR blockade but do not alter
mEPSC amplitude, strongly suggest that the effects are
presynaptic. Taken together, our data indicate that pre-
GlyRs tonically facilitate excitatory, spontaneous, action
potential-independent transmission in developing mouse
visual cortex.
PreGlyRs enhance neurotransmitter release via
heteromeric GlyRs and a depolarizing Cl− gradient
The gradient of [Cl−]i relative to [Cl−]o determines
whether GlyRs are depolarizing or hyperpolarizing
(Rivera et al. 1999; Stein & Nicoll, 2003). In early
development, high expression of NKCC1 maintains a high
[Cl−]i, which favours depolarizing GlyR currents. NKCC1
expression decreases and KCC2 expression increases
during development, reducing the [Cl−]i/[Cl−]o ratio,
thus favouring hyperpolarizing currents (Wang et al.
2002). To establish the role of Cl− transport in glycine
modulation of neurotransmitter release during the visual
cortex critical period, we tested the effects of the
selective NKCC1 inhibitor bumetanide (10 μM; Haas,
Figure 2. Exogenous glycine does not detectably alter evoked excitatory transmission in the developing
visual cortex
A, averaged data showing the effects of glycine (1 μM) on the amplitude of excitatory postsynaptic currents (EPSCs)
evoked by L4 stimulation and recorded in L2/3 pyramidal neurons in the presence of BMI (30 μM) and D,L-APV
(200 nM; n = 10, P > 0.05; paired t test). B, averaged data showing the input–output relationship of evoked L4
to L2/3 synaptic currents recorded in the presence or absence of glycine (1 μM; n = 9 for each group, P > 0.05;
RMANOVA). C, averaged paired-pulse ratio (PPR) of evoked L2/3 EPSCs recorded in the presence or absence of
glycine (1 μM; n = 11 for each group, P > 0.05; RMANOVA). ISI, inter-stimulus interval.
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1989) on spontaneous neurotransmission. Bumetanide
pre-incubation occluded the increase in neurotransmitter
release caused by glycine application (Fig. 4C; 102 ± 6%
of baseline compared with control 128 ± 8% of base-
Figure 3. Strychnine-sensitive GlyRs promote
neurotransmitter release
A, schematic of experimental design. Pre-incubation of strychnine
and D,L-2-amino-5-phosphonopentanoic acid (D,L-APV; indicated in
blue) was initiated 20 min prior to the start of whole-cell recordings
and maintained for the duration of the recording, while acute drugs
(strychnine, s; taurine, t; glycine, g; or D-serine, D) were applied after
a 10 min baseline period and then washed out after an additional
10 min. B, averaged data of normalized miniature excitatory
postsynaptic current (mEPSC) frequency demonstrates acute effects
of indicated drugs as a percentage of baseline. Asterisks denote
significance (P < 0.05). C, averaged normalized data demonstrate
that the pharmacological manipulations did not significantly alter
mEPSC amplitude. Sample sizes in B and C are given within the bars.
The mEPSC frequencies and amplitudes were normalized to the
averaged baseline levels before acute drug application.
line, P < 0.01; t test) without affecting mEPSC amplitude
(Fig. 4D; bumetanide + glycine, 103 ± 2% of base-
line compared with control 105 ± 6% of baseline,
P > 0.6). Together these results suggest that preGlyRs are
depolarizing in early development, at least in part due to
the high Cl− gradient established by NKCC1.
A developmental switch has been reported in the sub-
unit composition of GlyRs, from homomeric receptors
Figure 4. Heteromeric GlyRs require a favourable Cl− gradient
to promote neurotransmitter release
A, schematic of experimental design. Antagonists were applied
20 min (picrotoxin) or 60 min (bumetanide) prior to beginning
whole-cell recordings. After a 10 min baseline period, glycine was
applied for 10 min. B, cumulative probability distributions of
miniature excitatory postsynaptic current (mEPSC) frequency (Ba)
and amplitude (Bb) following glycine application (1 μM). Glycine
shortened inter-event interval, but not amplitude, in the presence of
picrotoxin. C, averaged normalized mEPSC frequency demonstrating
that pre-incubation with bumetanide (10 μM) blocked facilitation by
glycine (1 μM), whereas pre-incubation with picrotoxin (50 μM) had
little effect on glycine-induced increase in mEPSC frequency.
Asterisks denote significance (P < 0.05). D, averaged normalized
data demonstrate that no significant changes in mEPSC amplitude
were observed with any of the pharmacological manipulations.
Sample sizes in C and D are given within the bars. The mEPSC
frequencies and amplitudes were normalized to the averaged
baseline levels before acute drug application.
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containing only α subunits, to heteromeric receptors
containing bothα andβ subunits (Aguayo et al. 2004). This
subunit switch might alter the role of GlyRs in regulating
spontaneous neurotransmitter release. To examine this
possibility, we pre-incubated slices with picrotoxin
(50 μM), which at this dosage blocks homomeric but
not heteromeric GlyRs (Yoon et al. 1998), finding that
picrotoxin failed to prevent the glycine-mediated increase
in mEPSC frequency (Fig. 4C; 126 ± 8% of baseline
compared with control 121 ± 5% of baseline, P > 0.3;
t test). We saw similar results when we added D,L-APV
to the picrotoxin in a subset of interleaved experiments
(131 ± 8% of baseline, P > 0.1). These data suggest that
the glycine-responsive receptors are heteromeric GlyRs
containing both α and β subunits.
PreGlyR-mediated enhancement of neurotransmitter
release requires extracellular Ca2+
Excitatory neurotransmitter release generally relies
on increases in presynaptic intracellular Ca2+ levels
(Adam-Vizi, 1992; Sudhof, 2008). GlyR activity has been
linked to Ca2+ signaling in immature neurons of the spinal
cord and neocortex (Flint et al. 1998; Kirsch & Betz, 1998).
To establish a role for Ca2+ in preGlyR facilitation, we
examined the effects of glycine in nominally ‘Ca2+-free’
ACSF with the addition of the calcium chelator EGTA
(3 mM; ‘zero Ca2+’). The loss of external Ca2+ greatly
reduced mEPSC frequency prior to application of glycine
(33 ± 10% of baseline, P < 0.004; paired t test). Under this
zero Ca2+ condition, subsequent application of glycine
had no effect on neurotransmitter release, as measured
by mEPSC frequency (Fig. 5C; 101 ± 7% of baseline,
P > 0.5). This suggests that preGlyRs facilitate glutamate
release at these ages via a calcium-dependent increase in
neurotransmitter release.
To test whether preGlyR activation enhances neuro-
transmitter release by activating VGCCs, we examined the
effects of the non-selective VGCC inhibitor Cd2+ (200 μM)
on glycine-induced changes in neurotransmitter release.
Pre-incubation with Cd2+ prevented glycine facilitation of
transmitter release (Fig. 5C; 98 ± 9% of baseline compared
with control 117 ± 5% of baseline, P < 0.01; unpaired
t test), suggesting that GlyR-mediated depolarization
enhances neurotransmitter release by activating VGCCs.
Calcium influx can trigger neurotransmitter release either
by directly activating vesicular release machinery or by
triggering the release of Ca2+ from intracellular stores
(calcium-induced calcium release; Galante & Marty, 2003;
Neher & Sakaba, 2008). To examine the latter possibility,
we tested the effects of glycine on neurotransmitter release
after depleting intracellular Ca2+ stores by bath-applying
CPA (30 μM), a Ca2+ store ATPase inhibitor (Seidler et al.
1989; Emptage et al. 2001). Pre-incubation with CPA
Figure 5. Glycine-dependent neurotransmitter release
requires Ca2+ entry through VGCCs
Aa, schematic of experimental design. Antagonists (Cd2+ or
cyclopiazonic acid (CPA)) or a nominally Ca2+-free bath solution
(zero Ca2+) were applied 60 min prior to the start of whole-cell
recordings. After a 10 min baseline period, glycine was applied for
10 min. Ab, example whole-cell recording from a L2/3 pyramidal cell
bathed in zero Ca2+ ACSF depicting miniature excitatory
postsynaptic currents (mEPSCs) recorded at baseline and during bath
application of 1 μM glycine. B, cumulative probability distributions of
mEPSC frequency (Ba) and amplitude (Bb) following glycine
application (1 μM); glycine had no effect in zero Ca2+ ACSF. C,
averaged normalized mEPSC frequency demonstrating
pre-incubation in zero Ca2+ ACSF containing the calcium chelator
EGTA (3 mM) prevents glycine facilitation. Inclusion of Cd2+
(200 μM) in the ACSF also prevents glycine facilitation of mEPSC
frequency. CPA (30 μM) incubation has no effect on glycine
enhancement of mEPSC frequency. Asterisk denotes significance
(P < 0.05). D, averaged normalized mEPSC amplitude; no significant
changes were observed with any of the pharmacological
manipulations. Sample sizes in C and D are given within the bars.
The mEPSC frequencies and amplitudes were normalized to the
averaged baseline levels before glycine application.
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did not prevent glycine-mediated increases in mEPSC
frequency (Fig. 5C; 115 ± 6% of baseline compared with
control 116 ± 6% of baseline, P > 0.2). These data suggest
that, by depolarizing presynaptic terminals, GlyRs activate
VGCCs, and the ensuing Ca2+ entry directly enhances
spontaneous glutamatergic release.
GlyT1 activity supports tonic preGlyR activity
Extracellular glycine levels are tightly regulated
by the glycine transporters GlyT1 and GlyT2,
which are predominantly expressed in astrocytes and
neurons, respectively (Zafra et al. 1995a,b; Aragon &
Lopez-Corcuera, 2003; Eulenburg et al. 2005; although
see Raiteri & Raiteri, 2010). To determine whether glycine
transporters maintain extracellular glycine levels sufficient
for tonic enhancement of neurotransmitter release, we
used transporter-selective inhibitors. GlyT1 is blocked
by sarcosine (500 μM) or NFPS (100 nM), while GlyT2
can be blocked by Alx 1393 (200 nM; Xu et al. 2005;
Harsing et al. 2006). We pre-incubated slices in GlyT
inhibitors for a minimum of 1 h, and tested whether
these manipulations impaired tonic preGlyR activity by
measuring the effects of the GlyR antagonist strychnine
on mEPSC frequency and amplitude during continuous
application of sarcosine, NFPS or Alx 1393. Blockade of
GlyT1, but not GlyT2, prevented reductions in mEPSC
frequency by strychnine (Fig. 6C; sarcosine, 103 ± 7% of
baseline; NFPS, 97 ± 3% of baseline; Alx 1393, 82 ± 7%
of baseline, P < 0.02; ANOVA), suggesting that GlyT1
activity is necessary to support tonic preGlyR-mediated
neurotransmitter release. None of these manipulations
altered mEPSC amplitude (Fig. 6D; P > 0.05; ANOVA).
Because most GlyT1s are found on glia (Zafra et al.
1995a,b), we wanted to explore the possible involvement
of glia in supporting glycine-mediated neurotransmitter
release. To do this, we tested the effects of the astrocytic
toxin D,L-α-aminoadipic acid (D,L-αAA; 200 μM; Casper
& Reif-Lehrer, 1983; Huck et al. 1984; Khurgel et al. 1996)
on strychnine-sensitive spontaneous activity. D,L-αAA
pre-incubation (>1 h) prevented strychnine-induced
changes in spontaneous activity (Fig. 6C; 99 ± 3% of
baseline, P > 0.05; ANOVA). Taken together, these data
suggest that GlyT1, apparently associated with glial cells,
regulates extracellular glycine levels and thereby facilitates
excitatory spontaneous, action potential-independent
neurotransmitter release in the developing cortex.
To confirm that these manipulations did not affect
strychnine-sensitive neurotransmitter release by directly
altering GlyRs, we tested the effects of glycine following
pre-incubation with sarcosine, NFPS, Alx 1393 or
D,L-αAA. Glycine increased mEPSC frequency to a similar
degree even in the presence of GlyT1 and GlyT2
inhibitors (Fig. 6C; sarcosine, 132 ± 5% of baseline;
NFPS, 114 ± 3% of baseline; Alx 1393, 117 ± 6% of
baseline, P > 0.05; ANOVA), without affecting amplitude
(Fig. 6D; P > 0.05; ANOVA). Glycine also enhanced
mEPSC frequency to a similar degree in the presence
of D,L-αAA (Fig. 6C; D,L-αAA, 119 ± 5% of baseline,
P > 0.05; ANOVA), suggesting that preGlyRs can function
despite disruption of GlyT or astrocytic function. Thus,
multiple pharmacological manipulations support a role
for GlyT1, likely on astrocytes, for maintaining tonic
glycine-mediated spontaneous neurotransmitter release.
To provide direct evidence regarding the distribution of
GlyT1 in the visual cortex, we performed electron micro-
scopy with specific antibodies to determine its subcellular
localization. Because GlyT1 staining was incompatible
with classical glutaraldehyde fixation, the ultrastructure
was unavoidably compromised, but remained inter-
pretable. To minimize difficulties associated with anti-
body penetration, attention was focused on a zone
∼1–2 μm beneath the section surface that displayed highly
selective immunostaining. DAB reaction product was pre-
dominantly in fine processes within the neuropil. GlyT1
staining was predominantly astrocytic, though occasional
thin dendritic processes were also stained. These immuno-
positive astrocytic profiles were commonly situated in
close association with axospinous synapses (Fig. 7A–C).
PreGlyRs fail to enhance excitatory neurotransmitter
release after the critical period
Previous studies have found that chloride-fluxing channels
can shift from depolarizing to hyperpolarizing, although
there are regional differences in the timing of this shift
(Ben-Ari et al. 1994; Chen et al. 1996; Backus et al. 1998;
Tapia & Aguayo, 1998; Wang et al. 2005). Therefore,
we tested whether preGlyRs remain depolarizing and
tonically active in the visual cortex after the end of
the critical period. The data presented above were from
P13–18 mice. In contrast, glycine in more mature mice
(P30–40) no longer increased mEPSC frequency, but
instead significantly reduced it (Fig. 8D; 79 ± 6% of base-
line, P < 0.003; paired t test). We conclude that the effect
of glycine on neurotransmitter release switches during
development, sometime between P18 and P30 under our
recording conditions. We also asked whether preGlyRs
were tonically active at P30–40, as was observed in younger
mice. Strychnine application had no effect on neuro-
transmitter release (Fig. 8D; 99 ± 2% of baseline, P > 0.7),
indicating that the tonic activation of GlyRs was also lost
with age.
To confirm that the hyperpolarizing effect of glycine
in the adult was due to GlyR and not NMDAR
activation, we measured the effects of glycine after
pre-incubating slices in the GlyR antagonist strychnine
or the NMDAR antagonist D,L-APV. Strychnine, but
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not D,L-APV, abolished the effect of glycine application
on mEPSC frequency (Fig. 8D; strychnine + glycine,
99 ± 2% of baseline, P < 0.006 compared with glycine
alone; D,L-APV + glycine, 60 ± 2% of baseline, P > 0.05
compared with glycine alone; ANOVA). There was no
effect of these manipulations on mEPSC amplitude (Fig.
8E; P > 0.05), suggesting that GlyRs exert an inhibitory
presynaptic influence on neurotransmitter release in the
adult. Thus, while preGlyRs tonically facilitate glutamate
release in younger animals, they are hyperpolarizing in
older animals and no longer contribute to spontaneous,
action potential-independent neurotransmission.
Discussion
The present study demonstrates that preGlyRs tonically
enhance glutamate release in the visual cortex of young
mice (P13–18). This GlyR-mediated enhancement of
neurotransmitter release requires a depolarizing Cl−
gradient established by NKCC1 activity, and subsequent
calcium entry through VGCCs. These preGlyRs are
tonically activated by ambient glycine, which is regulated
through GlyT1 activity. In contrast, preGlyRs in adult
visual cortex lack tonic activity and instead exhibit
a hyperpolarizing effect. These data demonstrate an
age-dependent role for GlyRs in regulating glutamate
release in the neocortex.
Glycine-mediated effects on glutamate release
Glycine could influence neurotransmitter release in
a number of ways, but the two most parsimonious
explanations are through activation of NMDARs, where
glycine acts as an important co-agonist (Ahmadi et al.
2003), or through GlyRs located on the presynaptic bouton
(Dahan et al. 2003; Danglot et al. 2004). Indeed, NMDAR
activity can tonically facilitate neurotransmitter release in
the developing cortex (Woodhall et al. 2001; Corlew et al.
2007; Brasier & Feldman, 2008; Larsen et al. 2011). Our
Figure 6. The glial GlyT1 regulates extracellular glycine levels and glycine-dependent neurotransmitter
release
A, schematic of experimental design to test whether pre-incubation with GlyT antagonists or a gliotoxin blocks
effects of glycine and strychnine. Antagonists/toxin were applied 60 min prior to the start of recordings. After a
10 min baseline period, glycine (gly) or strychnine (str) was applied for 10 min. B, example whole-cell recordings
from L2/3 pyramidal cell bathed in sarcosine depicting miniature excitatory postsynaptic currents (mEPSCs) recorded
at baseline and during bath application of 1 μM glycine (Ba) or 3 μM strychnine (Bb). C, averaged normalized mEPSC
frequency demonstrates that pre-incubation with sarcosine, N-[3-(4′-fluorophenyl)-3-(4′-phenylphenoxy)propyl]
sarcosine (NFPS) or D,L-α-aminoadipic acid (D,L-αAA), but not the GlyT2-specific antagonist Alx 1393, prevents
the strychnine-induced reduction in mEPSC frequency. Pre-incubation with sarcosine, NFPS, Alx 1393 or D,L-αAA
had no effect on glycine-dependent facilitation. D, averaged normalized mEPSC amplitude; no significant changes
were observed with any of the pharmacological manipulations. The mEPSC frequencies and amplitudes in C and
D were normalized to the averaged baseline levels before glycine or strychnine application.
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Figure 7. GlyT1 are localized primarily on astrocytic processes
A, axon terminal (shaded yellow) makes synaptic contact with a dendritic spine (shaded blue). Electron-dense
DAB reaction product coding for GlyT1 is visible within an astrocytic profile lying adjacent to the spine. B, an
irregular astrocytic profile immunopositive for GlyT1 lies adjacent to two asymmetric synapses in the same electron
microscopic field. The astrocytic cytoplasm has been disrupted by the immune processing and the relatively weak
fixation necessary to preserve antigenicity. C, electron-dense reaction product in astrocytic profile lies between two
axodendritic synapses. The small lightly-immunostained profile on the bottom left is likely also to be astrocytic.
D, low-magnification montage shows immunostained astrocytic profile in a field of neuropil. E, axon terminal
and spine are enveloped by immunostained astrocytic processes. F, axospinous synapse lies adjacent to immuno-
positive astrocytic process; false-colour as in A. G, illustration depicting the mechanism of preGlyR facilitation of
neurotransmitter release. Abbreviations: AMPAR, AMPA receptor; AT, axon terminal; GlyR, glycine receptor; GlyT,
glycine transporter; NKCC1, Na+–K+–2Cl− cotransporter; Sp, spine; VGCC, voltage-gated calcium channel. Scale
bars: 200 nm.
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Figure 8. Strychnine-sensitive GlyRs decrease
neurotransmitter release but lack tonic effects in older mice
Aa, schematic diagram of experimental design. Antagonists
(strychnine or D,L-2-amino-5-phosphonopentanoic acid (D,L-APV))
were applied 20 min prior to the start of recordings. After a 10 min
baseline period, glycine (gly) or strychnine (str) was applied for
10 min. Ab, example whole-cell recording from a L2/3 pyramidal cell
depicting miniature excitatory postsynaptic currents (mEPSCs)
recorded at baseline and during bath application of 1 μM glycine in a
visual cortex slice from a P32 mouse. B, cumulative probability
distributions show effect of glycine (1 μM) on mEPSC frequency, but
not amplitude. C, cumulative probability distributions show no effect
of strychnine (3 μM) on mEPSC frequency or amplitude. D, averaged
normalized data from P28–35 mice demonstrating that glycine
(1 μM) reduced mEPSC frequency; application of strychnine (3 μM)
had no effect on mEPSC frequency at this age. Strychnine (3 μM) but
not D,L-APV (100 μM) prevented the glycine-dependent reduction in
mEPSC frequency. Asterisks denote significance (P < 0.05). E,
averaged normalized mEPSC amplitude; no significant changes were
observed with any of the pharmacological manipulations. Sample
sizes in D and E are given within the bars. The mEPSC frequencies
and amplitudes were normalized to the averaged baseline levels
before glycine or strychnine application.
results, together with previous literature showing that pre-
synaptic NMDARs are saturated at their glycine binding
sites (Li & Han, 2007), suggest that glycine enhances
glutamate release by activating GlyRs, not NMDARs.
How do GlyRs trigger neurotransmitter release? Neuro-
transmitter release is typically triggered by calcium
entry into the presynaptic terminal through VGCCs
(Augustine et al. 1987; Turner et al. 1992); thus we
were not surprised to find that glycine promotes neuro-
transmitter release in the developing visual cortex by
activating VGCCs. Whether preGlyRs depolarize pre-
synaptic membranes sufficiently to activate VGCCs has
been debated (Takahashi & Momiyama, 1993; Wu et al.
1999; Ishikawa et al. 2005). However, work addressing
the influence of GABA on neurotransmission has long
supported a role for presynaptic chloride currents in
bouton depolarization in the cerebral cortex (Trigo et al.
2008; Ruiz et al. 2010), as well as in the spinal cord
(for review, see Hochman et al. 2010). Our conclusion
that preGlyRs activate VGCCs in the developing visual
cortex is consistent with previous observations in other
brain regions (Turecek & Trussell, 2001), and raises the
possibility that these receptors are localized to the pre-
synaptic bouton, near VGCCs. However, we cannot rule
out other possible locations for GlyRs. For example, it is
conceivable that somatic GlyRs can trigger subthreshold
depolarizations sufficient to induce VGCC activity and
presynaptic transmitter release, as has been shown with
direct somatic depolarizations in the cerebellum (Christie
et al. 2011). Future studies are needed to identify both the
cell types that have preGlyRs and the precise subcellular
localization of these receptors. To date, GlyRs have been
localized to L3 and L5 pyramidal cells, cortical subplate
neurons, and Cajal-Retzius cells (Naas et al. 1991; Okabe
et al. 2004; and current study); we speculate that the ability
of preGlyR-mediated currents to activate VGCCs may be
common throughout the developing CNS.
GlyT1 contribution to preGlyR function
Ambient and released glycine must be tightly regulated for
normal neural function, and a number of disease states
are caused by dysregulation of glycine levels (discussed
below). Glycine is predominantly biosynthesized in the
mammalian liver (Sato et al. 1969); its regulation in
the brain is largely dictated by the glycine trans-
porters GlyT1 and GlyT2. These transporters have
distinct mechanisms of function and cellular localization;
GlyT1 transports glycine bidirectionally based on its
concentration gradient, whereas GlyT2 packages glycine
by the vesicular inhibitory amino acid transporter for
later release (Eulenburg et al. 2005). We took advantage
of the distinct pharmacology of glycine transporters
to show that GlyT1 is likely the critical transporter
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in setting the ambient extracellular glycine levels that
promote preGlyR-mediated glutamate release. Physio-
logically, circulating glycine has been measured to be in the
low micromolar range (Westergren et al. 1994), but GlyT1
activity is capable of reducing cleft glycine concentrations
to ∼150 nM (Attwell et al. 1993; Roux & Supplisson,
2000). During periods of glial depolarization and in some
pathophysiological conditions (e.g. ischemia or hypo-
xia), glycine can reach concentrations of 20–100 μM or
more (Baker et al. 1991; Phillis et al. 1994; Roux &
Supplisson, 2000); in these circumstances preGlyR activity
could increase spontaneous neurotransmitter release by
up to 42% (current study), potentially synchronizing
neurotransmitter release across active zones to generate
postsynaptic action potentials (Sharma & Vijayaraghavan,
2003).
In the brain, GlyT1 is found mainly on glia, whereas
GlyT2 is restricted to neurons (Zafra et al. 1995a,b; Aragon
& Lopez-Corcuera, 2003; Eulenburg et al. 2005; Raiteri &
Raiteri, 2010). Both neurons and astrocytes are capable of
glycine release (Jonas et al. 1998; Huang et al. 2004), but
they must first take up glycine from extracellular spaces via
transporters. We found that both GlyT1 antagonists and a
glial toxin prevent tonic preGlyR-mediated enhancement
of neurotransmitter release in the developing visual cortex.
These data collectively suggest that GlyT1 on astrocytes
controls ambient glycine levels and tonic preGlyR activity.
In light of our findings, glycine may need to be added to
the list of gliotransmitters, which now include glutamate,
ATP and D-serine (Perea & Araque, 2009).
PreGlyR activity in the adult
Similar to the depolarizing role of GABA receptors
during early neuronal development (Ben-Ari, 2002), pre-
GlyRs tonically facilitate neurotransmitter release in the
developing visual cortex. In contrast, preGlyRs are not
tonically active in more mature cortex and, when acutely
activated, they have an inhibitory effect on glutamate
release. The significance of this developmental shift is
not yet known, although it may reflect the need for
increased inhibitory drive to terminate the critical period
of cortical plasticity (Fagiolini & Hensch, 2000; Feldman,
2000; Hensch, 2004; Harauzov et al. 2010). While it is
likely that all GlyRs undergo a developmental shift in their
function, we cannot rule out the possibility that there are
also distinct microdomains where GlyRs have differential
hyperpolarizing versus depolarizing effects at any given
age.
Importance of GlyRs
Glycine is a primary inhibitory neurotransmitter in
the spinal cord and brainstem (Rajendra et al. 1997),
and contributes to inhibition in the hippocampus
(Chattipakorn & McMahon, 2003; Song et al. 2006).
Postsynaptic GlyRs are also important for some
forms of short-term plasticity (Zhang et al. 2006),
the induction of long-term depression (Chen et al.
2011), shunting inhibition (Keck et al. 2008) and the
osmoregulation of neuronal activity (Deleuze et al. 2005).
However, the contribution of depolarizing preGlyRs to
shaping neurotransmitter release has only recently been
appreciated. Spontaneous activity-independent neuro-
transmitter release has recently been shown to stabilize
dendritic spines (McKinney et al. 1999), regulate dendritic
protein synthesis (Sutton et al. 2004) and shape the
chemistry (locally and globally) of postsynaptic cells
(Otsu & Murphy, 2003; Sharma & Vijayaraghavan,
2003), suggesting that the maintenance of spontaneous
activity by preGlyRs in the developing visual cortex likely
contributes to proper circuit formation. While we were
unable to identify a role for preGlyRs in adjusting action
potential-driven transmitter release under our recording
conditions, such a role might be identified with other
parameters or conditions. In support of this idea, pre-
vious studies have shown that presynaptic NMDARs can
enhance spontaneous neurotransmitter release in the pre-
sence of brain-derived neurotrophic factor, but these
receptors failed to enhance evoked transmitter release
unless VGCC activity was reduced (Madara & Levine,
2008). Future experiments are needed to determine
whether there are conditions that unmask a role for pre-
GlyRs in evoked transmitter release.
The importance of glycinergic transmission is under-
scored by the severe disease states and behavioral deficits
caused by mutations that alter GlyR subunits or glycine
homeostasis. Many of these clinical signs likely reflect
glycine’s key role as inhibitory transmitter in the brain stem
and spinal cord; for example, improper GlyR clustering
and synapse formation results in deficits in touch-evoked
responses and escape behaviors in zebrafish (Ogino et al.
2011). Likewise, GlyR mutations in mice reduce the
ethanol sensitivity to motor incoordination and righting
reflexes (Findlay et al. 2002). However, other effects target
higher levels of the neuraxis. For example, GlyR mutations
not only increase startle responses in mice (Harvey et al.
2008), but also disrupt amygdala-associated anxiety-like
behaviors (McCool & Chappell, 2007).
Evidence from clinical practice strongly implicates
glycine in neocortical development and function.
Infantile and late-onset hyperglycinemia present with
mild to moderate mental retardation, agitated delirium,
vertical gaze palsy, behavioral hyperirritability, aggressive
outbursts and seizures (Singer et al. 1989; Steiner et al.
1996; Dinopoulos et al. 2005). In addition to these chronic
changes in glycine homeostasis, acute manipulations
that can affect glycinergic signaling also have profound
neurological consequences. For example, elevations in
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circulating glycine concentration (which can occur with
surgical complications) have been correlated with a
decrease in cognition and spatial acuity, as well as visual
disturbances that reverse once glycine returns to base-
line levels (Mizutani et al. 1990; Nilsson & Hahn, 1994;
Radziwill et al. 1997). Glycine disturbances have also been
suggested in other diseases, including schizophrenia and
epilepsy, where some common treatments targeted at the
glycine-binding site of NMDARs affect glycine homeo-
stasis (Waziri, 1988; Birdsall, 1998; de Koning et al. 1998;
Farber et al. 1999; Javitt, 2009), or have been shown to
alter GlyR functions directly (Rigo et al. 2002).
Despite the fact that GlyRs are important targets for
many therapeutic drugs (Deutsch et al. 1983; Jaeken,
2002), surprisingly few studies have considered the
possibility that preGlyRs can influence neurotransmitter
release (Chepkova et al. 2002; Zhang et al. 2006; Lee
et al. 2009). Our results provide mechanistic insight into
the role of preGlyRs in facilitating excitatory neuro-
transmitter release, and the switch of preGlyRs to an
inhibitory role with maturation. Besides providing new
insights into development of cortical circuits, our findings
identify synaptic functions likely to be impacted by GlyR
dysfunction.
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